Efficacy and Safety of 2 Doses of TEV-48125 Versus Placebo for the Prevention of Chronic Migraine
- Study Title
- Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
- Teva Identifier
- TV48125-CNS-30049 | 2015-004549-23
- ClinicalTrials.gov Identifier
- NCT02621931
- Study Status
- Completed
- Trial Condition(s)
- Migraine
- Interventions
- Drug: Fremanezumab | Drug: Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 70 Years
- Trial Duration
- March 22, 2016 - April 11, 2017
- Phase
- Phase 3
